血清胶质纤维酸性蛋白:视神经脊髓炎谱系疾病生物标志物
本研究基于N-MOmentum随机对照试验,在215例视神经脊髓炎谱系疾病(NMOSD)患者中检测血清胶质纤维酸性蛋白(sGFAP)浓度,发现基线sGFAP≥170 pg/ml者发作风险更高,发作后sGFAP升高且与发作严重程度相关,而inebilizumab治疗可抑制此升高。
要点
- 基线sGFAP≥170 pg/ml的NMOSD患者发作风险显著增高(HR 3.09)。
- 发作1周内sGFAP中位数从168.4升至2160.1 pg/ml,且与发作严重程度相关。
- inebilizumab治疗组未观察到发作相关的sGFAP升高。
核心结论
- 血清GFAP可能作为NMOSD疾病活动、发作风险及治疗效应的生物标志物。
研究设计与样本
- N-MOmentum为前瞻性、多中心、双盲、安慰剂对照、随机临床试验,纳入215例成人NMOSD患者(92% AQP4-IgG血清阳性),检测1260份连续及发作相关样本的sGFAP,并设健康供者和复发缓解型多发性硬化对照。
主要发现
- 基线时62例(29%)sGFAP≥170 pg/ml(≥健康供者均值2个标准差),其发生裁定发作的风险高于低基线者(HR 3.09,95%CI 1.6-6.1,p=0.001)。
- 发作1周内sGFAP中位数从基线168.4 pg/ml(IQR 128.9-449.7)升至2160.1 pg/ml(IQR 302.7-9455.0),p=0.0015。
- sGFAP升高与发作严重程度相关:轻微发作中位倍数变化1.06(IQR 0.9-7.4),严重发作34.32(IQR 8.7-107.5),p=0.023。
- 发作相关sGFAP升高主要见于安慰剂组(倍数变化20.2,IQR 4.4-98.3,p=0.001),inebilizumab组未观察到(倍数变化1.1,IQR 0.8-24.6,p>0.05)。
- 5例(28%)基线sGFAP升高者报告神经系统症状,导致未裁定发作评估。
关键数值与推荐
- sGFAP高浓度定义为≥170 pg/ml(≥健康供者均值2个标准差)。
临床怎么用
- sGFAP或可用于监测NMOSD疾病活动、评估发作风险及治疗反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Blood tests to monitor disease activity, attack severity, or treatment impact in neuromyelitis optica spectrum disorder (NMOSD) have not been developed. This study investigated the relationship between serum glial fibrillary acidic protein (sGFAP) concentration and NMOSD activity and assessed the impact of inebilizumab treatment. METHODS: N-MOmentum was a prospective, multicenter, double-blind, placebo-controlled, randomized clinical trial in adults with NMOSD. sGFAP levels were measured by single-molecule arrays (SIMOA) in 1,260 serial and attack-related samples from 215 N-MOmentum participants (92% aquaporin 4-immunoglobulin G-seropositive) and in control samples (from healthy donors and patients with relapsing-remitting multiple sclerosis). RESULTS: At baseline, 62 participants (29%) exhibited high sGFAP concentrations (≥170 pg/ml; ≥2 standard deviations above healthy donor mean concentration) and were more likely to experience an adjudicated attack than participants with lower baseline concentrations (hazard ratio [95% confidence interval], 3.09 [1.6-6.1], p = 0.001). Median (interquartile range [IQR]) concentrations increased within 1 week of an attack (baseline: 168.4, IQR = 128.9-449.7 pg/ml; attack: 2,160.1, IQR = 302.7-9,455.0 pg/ml, p = 0.0015) and correlated with attack severity (median fold change from baseline [FC], minor attacks: 1.06, IQR = 0.9-7.4; major attacks: 34.32, IQR = 8.7-107.5, p = 0.023). This attack-related increase in sGFAP occurred primarily in placebo-treated participants (FC: 20.2, IQR = 4.4-98.3, p = 0.001) and was not observed in inebilizumab-treated participants (FC: 1.1, IQR = 0.8-24.6, p > 0.05). Five participants (28%) with elevated baseline sGFAP reported neurological symptoms leading to nonadjudicated attack assessments. INTERPRETATION: Serum GFAP may serve as a biomarker of NMOSD activity, attack risk, and treatment effects. ANN NEUROL 2021;89:895-910.
引用
- Aktas O, Smith MA, Rees WA, et al. Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker. Ann Neurol. 2021. PMID: 33724534. doi:10.1002/ana.26067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。